Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 7, 2020

Alexion to start Soliris in COVID-19 Phase II trial

By Duncan West

Alexion Pharmaceuticals is set to enter the COVID-19 drug development race in the next few days via a single-arm, 100-patient Phase II trial investigating Soliris (eculizumab), a source familiar with the trial has revealed to GlobalData.

If this Phase II trial delivers a positive risk-benefit ratio, it would then pave the way for a 300-patient, randomised trial that would start shortly after. The Phase II trial will have sites in the US and Europe and is targeted to run for two weeks and the trial will have a primary endpoint looking into patient mortality between three-to-four weeks, the source said.

Read the full story

Related Companies

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU